For instance, high levels of sPD-1 in plasma or serum have been positively associated with poor clinical significance in patients with renal cell carcinoma [1,24], ovarian cancer [19], triple-negative breast cancer [27], and pancreatic ductal adenocarcinoma [29]. This evidence concerns the gene HOXD13 and hereditary clear cell renal cell carcinoma.